ISIS 1 Trial: Difference between revisions
No edit summary |
Adeeljamil (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
{{EH}} | |||
In ISIS 1 patients were randomized to treatment with either atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days) or placebo (n=16,027). <ref name="pmid2873379">{{cite journal |author= |title=Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group |journal=Lancet |volume=2 |issue=8498 |pages=57–66 |year=1986 |month=July |pmid=2873379 |doi= |url=}}</ref> Atenolol administration was associated with a 15% relative risk reduction in cardiovascular mortality over the first seven days (3.89% versus 4.57%, 2p = 0.04). The combined endpoint of death, cardiac arrest, and reinfarction was also signifcantly reduced (2p < 0.0002). There was a consistent benefit across all subgroups. Following the initial treatment over the first 7 days, the benefit was maintained and slightly fewer events were accrued such at that 1 year, cardiovascular death was significantly lower among patients treated with atenolol (10.7% versus 12.0%, 2p < 0.01). | In ISIS 1 patients were randomized to treatment with either atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days) or placebo (n=16,027). <ref name="pmid2873379">{{cite journal |author= |title=Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group |journal=Lancet |volume=2 |issue=8498 |pages=57–66 |year=1986 |month=July |pmid=2873379 |doi= |url=}}</ref> Atenolol administration was associated with a 15% relative risk reduction in cardiovascular mortality over the first seven days (3.89% versus 4.57%, 2p = 0.04). The combined endpoint of death, cardiac arrest, and reinfarction was also signifcantly reduced (2p < 0.0002). There was a consistent benefit across all subgroups. Following the initial treatment over the first 7 days, the benefit was maintained and slightly fewer events were accrued such at that 1 year, cardiovascular death was significantly lower among patients treated with atenolol (10.7% versus 12.0%, 2p < 0.01). | ||
| Line 10: | Line 12: | ||
[[Category:Randomized trials]] | [[Category:Randomized trials]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
{{SIB}} | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 17:47, 26 April 2009
|
WikiDoc Resources for ISIS 1 Trial |
|
Articles |
|---|
|
Most recent articles on ISIS 1 Trial Most cited articles on ISIS 1 Trial |
|
Media |
|
Powerpoint slides on ISIS 1 Trial |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ISIS 1 Trial at Clinical Trials.gov Clinical Trials on ISIS 1 Trial at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ISIS 1 Trial
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on ISIS 1 Trial Discussion groups on ISIS 1 Trial Patient Handouts on ISIS 1 Trial Directions to Hospitals Treating ISIS 1 Trial Risk calculators and risk factors for ISIS 1 Trial
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for ISIS 1 Trial |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
In ISIS 1 patients were randomized to treatment with either atenolol (5-10 mg iv immediately, followed by 100 mg/day orally for 7 days) or placebo (n=16,027). [1] Atenolol administration was associated with a 15% relative risk reduction in cardiovascular mortality over the first seven days (3.89% versus 4.57%, 2p = 0.04). The combined endpoint of death, cardiac arrest, and reinfarction was also signifcantly reduced (2p < 0.0002). There was a consistent benefit across all subgroups. Following the initial treatment over the first 7 days, the benefit was maintained and slightly fewer events were accrued such at that 1 year, cardiovascular death was significantly lower among patients treated with atenolol (10.7% versus 12.0%, 2p < 0.01).